A Comparison of Denosumab Versus Zoledronic Acid for the Prevention of Skeletal-Related Events in Breast Cancer Patients with Bone Metastases.
Alison Stopeck(National Cancer Centre Japan), Ada Braun(National Cancer Centre Japan), Denise A. Yardley(Sarah Cannon), Roger Dansey(Memorial Sloan Kettering Cancer Center), Qi Jiang(National Cancer Centre Japan), Yutaka Fujiwara(Aichi Cancer Center), Richard de Boer(Western Hospital), S. Jun(Amgen (United States)), Michelle Fan(National Cancer Centre Japan), Mikhail Lichinitser(National Cancer Centre Japan), K. Tonkin
Cited by 21
Related Papers
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
|Journal of Clinical Oncology|2010|1.6k
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
|Journal of Clinical Oncology|2011|1.3k